Lipocine Reports Q3 2026 Revenue Growth and Earnings Beat
Lipocine (LPCN) reported third-quarter financial results for the period ending September 30, 2026, significantly exceeding analyst expectations. The company posted GAAP earnings per share of -$0.08, outperforming estimates by $0.27, and reported revenue of $2.29 million, which surpassed projections by $2.13 million. The massive year-over-year revenue increase of 1,981.8% was driven primarily by a shift in revenue composition. While the previous year's revenue consisted solely of TLANDO royalties, the current quarter benefited from $2.1 million in license and collaboration revenue alongside $190,000 in royalty income.
Topics: earnings beat license revenue revenue growth royalty revenue